Napredna pretraga

Pregled bibliografske jedinice broj: 514933

Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules


Krajna, Ana; Pavićević, Radomir; Bubanović, Gordana; Alerić, Ivan; Pavlović, Ladislav; Popović-Grle, Sanja
Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules // European Respiratory Journal / Sterk, Peter J ; Rabe, Klaus F (ur.).
Sheffield: ERS Journals Ltd., 2003. str. 9s-9s (predavanje, međunarodna recenzija, sažetak, znanstveni)


Naslov
Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules

Autori
Krajna, Ana ; Pavićević, Radomir ; Bubanović, Gordana ; Alerić, Ivan ; Pavlović, Ladislav ; Popović-Grle, Sanja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Respiratory Journal / Sterk, Peter J ; Rabe, Klaus F - Sheffield : ERS Journals Ltd., 2003, 9s-9s

Skup
13th ERS annual congress

Mjesto i datum
Beč, Austrija, 27.9-1.10.2003

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CYFRA 21-1; tumor marker

Sažetak
Introduction: Single pulmonary nodules (SPNs) still represent a great challenge in pulmonary diadnostics. Biodynamic approach has been applied to determine wether tumor marker CYFRA 21-1 can be used as an early parameter of separation of non-small cell lung camcer (NSCLC) from other SPNs. Patients&methods: The study includes 431 patients with radiological finding of SPN that is not suitable from transthoracic and videothoracoscopic diagnostics. CYFRA 21-1 level was measured by electrochemiluminescent immunoassay at first admission and durinfg the first control check (1-3 months later). After taht period, the final diagnosis has been made and all the patient underwent surgical treatment. eight pathohistological groups were obtained after the surgery: carcinoid tumor, hamartoma, adenocarcinoma stage IA and IB, Squamous cell carcinoma stage IA, Hodgkin's diseases, pulmonary metastases and tuberculoma. Results: Kruskal-Wallis ANOVA proved significantd differences between 8 groups, both in first and second measurement (p=0, 0001). Patients with AD IB showed the greatest distinction from all other groups. Comparison of all other groups with each other showed the most discriminatory power of difference between two measurements. Patients with NSCLC differed significantly from all other groups, but did not differ between themselves. Conclusions: CYFRA 21-1 can be used in differential diagnosis of SPNs for early detection of NSCLC using two measurements because the dynamics of CYFRA 21-1 level divides primary NSCLC from other SPNs.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Kliničke medicinske znanosti



POVEZANOST RADA


Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE